Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes (Phase 2)
Beyond GI AEs, semaglutide was found to associate with a higher incidence of gallbladder-related disorders, primarily cholelithiasis [13, 40, 42, 44,45,46], and acute pancreatitis [13, 39, 42, 44] compared with placebo
In the case of Vitamin B12, more is not necessarily better
"Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes"
The Phase 2 trial reference point The Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023) enrolled 338 adults across placebo and retatrutide arms at 1, 4, 8, and 12 mg weekly
Appetite Suppression Differences Most people report powerful appetite suppression on both pure GLP-1 agonists and dual agonists